Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy

Inclusion Criteria: * Males or females aged ≥ 18 years * Coronary artery disease with a clinically diagnosed peripheral neuropathy * Willing and able to provide signed informed consent and Health Insurance Portability and Accountability Act (HIPAA) authorization * Willing and able to comply with the requirements of the protocol and follow directions from the clinic staff Exclusion Criteria: * History of allergy or intolerance to ranolazine * Any condition or concomitant medication that would have precluded the safe use of ranolazine as outlined in the prescribing information sheet (see Appendix E) * In the judgment of the investigator, any clinically-significant ongoing medical condition that might jeopardize the patient's safety or interfere with the absorption, distribution, metabolism or excretion of the study drug * In the judgment of the investigator, clinically-significant abnormal physical findings during screening (excluding the patient's peripheral neuropathy condition) * Use of any experimental or investigational drug or device within 30 days prior to screening * Pregnant or breast feeding, or (if premenopausal), not practicing an acceptable method of birth control (as detailed in Inclusion Criterion 4) * Had received prior treatment with, or investigational exposure to, ranolazine within 7 days prior to randomization * Clinically significant hepatic impairment * Had end-stage renal disease requiring dialysis * Psychological or addictive disorders (not limited to, but including drug and/or alcohol dependency) that may have precluded patient consent or compliance, or that may have confounded study interpretation * Positive pregnancy test at Baseline (pre-randomization, Day 0)